Gln151 of HIV-1 reverse transcriptase acts as a steric gate towards clinically relevant acyclic phosphonate nucleotide analogues

Antiviral Therapy

Volumn 13, Issue 1, 2008, Pages 115-124

  Frangeul, Antoine ^a   Bussetta, Cécile ^a   Deval, Jérôme ^a   Barral, Karine ^a   Alvarez, Karine ^a   Canard, Bruno ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACYCLIC NUCLEOTIDE PHOSPHONATE DERIVATIVE; ADEFOVIR; ADEFOVIR DIPHOSPHATE; ALANINE; ARGININE; CIDOFOVIR; CIDOFOVIR DIPHOSPHATE; GLUTAMINE; NUCLEOTIDE DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PYROPHOSPHATE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; TENOFOVIR DIPHOSPHATE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CATALYSIS; DRUG DNA BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR INTERACTION; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STEADY STATE; STEREOSPECIFICITY; STRUCTURE ANALYSIS;

ADENINE; ANTI-HIV AGENTS; BINDING SITES; CYTOSINE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HIV REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHONIC ACIDS; PROTEIN CONFORMATION;

EID: 42149127570     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Barre-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871.
2. Gallo RC, Sarin PS, Gelmann EP, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983; 220:865-867.
3. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984; 224:497-500.
4. De Clercq E. Antiviral drugs: current state of the art. J Clin Virol 2001; 22:73-89.
5. Larder BA, Stammers DK. Closing in on HIV drug resistance. Nat Struct Biol 1999; 6:103-106.
6. Sarafianos SG, Das K, Ding J, Boyer PL, Hughes SH, Arnold E. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem Biol 1999; 6:R137-R146.
7. Selmi B, Deval J, Boretto J, Canard B. Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediatea resistance to nucleoside analogues. Antivir Ther 2003; 8:143-154.
8. Sluis-Cremer N, Arion D, Parniak MA. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell Mol Life Sci 2000; 57:1408-1422.
9. Huang H, Chopra R, Verdine GL, Harrison SC. 1998. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282:1669-1675.
10. Deval J, Selmi B, Boretto J, et al. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues. J Biol Chem 2002; 277:42097-42104.
11. Feng JY, Anderson KS. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 1999; 38:9440-9448.
12. Krebs R, Immendorfer U, Thrall SH, Wohrl BM, Goody RS. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry 1997; 36:10292-10300.
13. Gao HQ, Boyer PL, Sarafianos SG, Arnold E, Hughes SH. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J Mol Biol 2000; 300:403-418.
14. Sarafianos SG, Das K, Clark Jr. et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc Natl Acad Sci U S A 1999; 96:10027-10032.
15. Hsu M, Inouye P, Rezende L et al. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res 1997; 25:4532-4536.
16. Oude Essink BB, Back NK, Berkhout B. Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase. Nucleic Acids Res 1997; 25:3212-3217.
17. Cramer J, Strerath M, Marx A, Restle T Exploring the effects of active site constraints on HIV-1 reverse transcriptase DNA polymerase fidelity. J Biol Chem 2002; 277:43593-13598.
18. Strerath M, Cramer J, Restle T, Marx A. Implications of active site constraints on varied DNA polymerase selectivity. J Am Chem Soc 2002; 124:11230-11231.
19. Cases-Gonzalez CE, Gutierrez-Rivas M, Menendez-Arias L. Coupling ribose selection to fidelity of DNA synthesis. The role of Tyr-115 of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem 2000; 275:19759-19767.
20. Martin-Hernandez AM, Domingo E, Menendez-Arias L. Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis. EMBO J 1996; 15:4434-1442.
21. Martin-Hernandez AM, Gutierrez-Rivas M, Domingo E, Menendez-Arias L. Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115. Nucleic Acids Res 1997; 25:1383-1389.
22. Tuske S, Sarafianos SG, Clark AD, Jr., et al. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol 2004; 11:469-474.
23. Suo Z, Johnson KA. Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine. / Biol Chem 1998; 273:27250-27258.
24. Boretto J, Longhi S, Navarro JM, Selmi B, Sire J, Canard B. An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase. Anal Biochem 2001; 292:139-147.
25. Brandis JW, Edwards SG, Johnson KA. Slow rate of phosphodiester bond formation accounts for the strong bias that Taq DNA polymerase shows against 2′,3′-dideoxynucleotide terminators. Biochemistry 1996; 35:2189-2200.
26. Roussel A, Cambillau C. 1991. p. 97. In S. Graphics (ed.), Silicon Graphics Directory, Mountain View, CA.
27. Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005; 26:1781-1802.
28. Kool ET. Active site tightness and substrate fit in DNA replication. Annu Rev Biochem 2002; 71:191-219.
29. Johnston E, Dupnik KM, Gonzales MJ, et al. Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations. AIDS 2005; 19:731-733.
30. Paolucci S, Baldanti F, Maga G et al. Gln145Met/Leu changes in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nucleoside and nonnucleoside analogs and impair virus replication. Antimicrob Agents Chemother 2004; 48:4611-4617.
31. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother 2000; 44:2109-2117.
32. Winters MA, Coolley KL, Cheng P, et al. Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitors. J Virol 2000; 74:10707-10713.
33. Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther 1999; 4:87-94.
34. White KL, Margot NA, Wrin T, Petropoulos CJ, Miller MD, Naeger LK. Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother 2002; 46:3437-3446.
35. Deval J, White KL, Miller MD et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004; 279:509-516.
36. Doublie S, Tabor S, Long AM, Richardson CC, Ellenberger T. Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 A resolution. Nature 1998; 391:251-258.
37. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16:569-596.
38. Naesens L, Balzarini J, Bischofberger N, De Clercq E. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2- phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother 1996; 40:22-28.
39. Selmi B, Boretto J, Sarfati SR, Guerreiro C, Canard B. Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue. J Biol Chem 2001; 276:48466-48472.
40. De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4:928-940.
41. Johnson AA, Ray AS, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001; 276:40847-40857.
42. Li Y, Korolev S, Waksman G. Crystal structures of open and closed forms of binary and ternary complexes of the large fragment of Thermus aquaticus DNA polymerase I: structural basis for nucleotide incorporation. EMBO J 1998; 17:7514-7525.
43. Tabor S, Richardson CC. A single residue in DNA polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy- and dideoxyribonucleotides. Proc Natl Acad Sci U S A 1995; 92:6339-6343.
44. Das K, Xiong X, Yang H, et al. Molecular modelling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75:4771-4779.